Regentis Biomaterials grants 24,826 options to director
Valentine Keith reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Valentine Keith reported acquisition or exercise transactions in this Form 4 filing.
Regentis Biomaterials Ltd. director Keith Valentine received a grant of 24,826 employee stock options to buy ordinary shares at $2.16 per share. The grant was approved by the board on May 28, 2026, subject to shareholder approval obtained July 9, 2026. The options vest in 12 quarterly installments starting August 28, 2026 and fully vest on May 28, 2029, and expire on May 28, 2036. Following this grant, Valentine holds options for 24,826 shares from this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 24,826 shares
Grant/Award
1 txn
Insider
Valentine Keith
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) F1, F2 | 24,826 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 24,826 contracts (Direct)
Footnotes (2)
- F1. This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
- F2. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029.
Key Figures
Options granted: 24,826 options
Exercise price: $2.16 per share
Total options after grant: 24,826 options
+5 more
8 metrics
Options granted
24,826 options
Employee Stock Option grant to director Keith Valentine
Exercise price
$2.16 per share
Conversion or exercise price of the employee stock options
Total options after grant
24,826 options
Total derivative securities held following this grant
Initial vesting fraction
1/12
Portion of options vesting on August 28, 2026
Grant board approval date
May 28, 2026
Board of Directors approved the option grant on this date
Shareholder approval date
July 9, 2026
Shareholders approved the option grant on this date
Full vesting date
May 28, 2029
Date on which the options are scheduled to be fully vested
Option expiration date
May 28, 2036
Date on which the options expire if unexercised
Key Terms
Employee Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Employee Stock Option (Right to Buy) financial
"Security title reported as "Employee Stock Option (Right to Buy)" for the grant"
exercise price financial
"The options have a conversion or exercise price of $2.1600 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The options carry an expiration date of 2036-05-28 for this grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did REGENTIS BIOMATERIALS (RGNT) report for Keith Valentine?
Regentis Biomaterials reported that director Keith Valentine received a grant of 24,826 employee stock options. These options allow him to buy ordinary shares at a fixed exercise price, subject to a multi-year vesting schedule and prior shareholder approval.
What is the exercise price of Keith Valentine’s new stock options in RGNT?
The granted options have an exercise price of $2.16 per share. This is the price at which Valentine can purchase Regentis Biomaterials ordinary shares once the options vest, providing potential value if the market price exceeds this level in the future.
How do the 24,826 RGNT stock options granted to Keith Valentine vest over time?
The 24,826 options vest in twelve equal quarterly installments. One-twelfth vests on August 28, 2026, with additional one-twelfth tranches vesting every three months, fully vesting on May 28, 2029, assuming continuous employment through each vesting date.
When were Keith Valentine’s RGNT option grants approved and when do they expire?
The option grant was approved by the board on May 28, 2026, subject to shareholder approval obtained on July 9, 2026. The options carry a long-term horizon, with an expiration date of May 28, 2036 if they are not exercised earlier.
How many RGNT options does Keith Valentine hold after this Form 4 transaction?
Following this reported transaction, Keith Valentine holds 24,826 employee stock options from this grant. These options each relate to one underlying ordinary share and are subject to the vesting and expiration terms set out in the grant documentation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
